H.pylori gastritis guideline recommendation: Difference between revisions

Jump to navigation Jump to search
Line 52: Line 52:
|
|
* Populations at higher risk for gastric cancer
* Populations at higher risk for gastric cancer
|}
{| class="wikitable"
!
!
!
!
|-
|
|
|
|
|-
|
|
|
|
|-
|
|
|
|
|}
|}

Revision as of 15:04, 16 January 2017

Helicobacter pylori infection Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Gastritis
Peptic ulcer disease
Gastric adenocarcinoma
MALT lymphoma

Causes

Differentiating Helicobacter pylori infection from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Guideline Recommendation

ACG guidelines
ESPGHAN and NASPGHAN guidelines

History and Symptoms

Physical Examination

Diagnostic tests

Endoscopic tests
Nonendoscopic tests

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

H.pylori gastritis guideline recommendation On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of H.pylori gastritis guideline recommendation

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on H.pylori gastritis guideline recommendation

CDC on H.pylori gastritis guideline recommendation

H.pylori gastritis guideline recommendation in the news

Blogs on H.pylori gastritis guideline recommendation

Directions to Hospitals Treating Helicobacter pylori infection

Risk calculators and risk factors for H.pylori gastritis guideline recommendation

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yamuna Kondapally, M.B.B.S[2]

Overview

ACG recommendations

Recommendation
  • Testing for H. pylori infection is indicated in patients with active peptic ulcer disease, a past history of documented peptic ulcer, or gastric MALT lymphoma.
  • The test-and-treat strategy for H. pylori infection is a proven management strategy for patients with uninvestigated dyspepsia who are under the age of 55 yr and have no “alarm features” (bleeding, anemia, early satiety, unexplained weight loss, progressive dysphagia, odynophagia, recurrent vomiting, family history of GI cancer, previous esophagogastric malignancy).
Indications for Diagnosis and Treatment of H.pylori Infection
Established
  • Active peptic ulcer disease (gastric or duodenal ulcer)
  • Confirmed history of peptic ulcer disease (not previously treated for H. pylori)
  • Gastric MALT lymphoma (low grade)
  • After endoscopic resection of early gastric cancer
  • Uninvestigated dyspepsia (depending upon H. pylori prevalence)
Controversial
  • Nonulcer dyspepsia
  • Gastroesophageal reflux disease
  • Persons using nonsteroidal antiinflammatory drugs
  • Unexplained iron deficiency anemia
  • Populations at higher risk for gastric cancer